A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset.
The effects of the selective and reversible MAOB inhibitor Ro19-6327 on parkinsonism in common marmosets, induced by MPTP were studied. Combined administration of Ro19-6327 with benserazide/levodopa potentiated the effects of levodopa to reverse akinesia. In a microdialysis study, the administration of Ro19-6327 was found to minimize the increase in metabolites of dopamine (DA) following injection of levodopa. These results suggest that Ro19-6327 suppresses the metabolism of DA, resulting in increased effects of levodopa on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Thus, Ro19-6327 should be useful in the treatment of patients with Parkinson's disease.
Nomoto
M
M
Department of Pharmacology, Kagoshima University School of Medicine, Japan.
Fukuda
T
T
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002144:Callithrix; D003956:Dialysis / Q000379:methods; D004347:Drug Interactions; D005260:Female; D007980:Levodopa / Q000494:pharmacology; D008124:Locomotion / Q000187:drug effects; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy* / Q000209:etiology; D010848:Picolinic Acids / Q000494:pharmacology*
D008996:Monoamine Oxidase Inhibitors; D010848:Picolinic Acids; C059303:lazabemide; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine